Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 103 million in Q1 2024, a 22% increase from SAR 84.4 million a year earlier.
| Item | Q1 2023 | Q1 2024 | Change |
|---|---|---|---|
| Revenues | 300.85 | 385.46 | 28.1 % |
| Gross Income | 199.61 | 249.40 | 24.9 % |
| Operating Income | 93.91 | 126.58 | 34.8 % |
| Net Income | 84.40 | 102.97 | 22.0 % |
| Average Shares | 70.00 | 70.00 | - |
| EPS (Riyals) | 1.21 | 1.47 | 22.0 % |
| Item | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Revenues | 207.86 | 385.46 | 85.4 % |
| Gross Income | 118.86 | 249.40 | 109.8 % |
| Operating Income | 42.24 | 126.58 | 199.7 % |
| Net Income | 44.48 | 102.97 | 131.5 % |
| Average Shares | 70.00 | 70.00 | - |
| EPS (Riyals) | 0.64 | 1.47 | 131.5 % |
The positive performance was driven by the increase in sales, which were slightly offset by the devaluation impact from the Egyptian pound.
Sequentially, net profit jumped 131.5% from SAR 44.48 million in Q4 2023 on higher sales, improvement in gross margin, in addition to better absorption of operating expenses.
Shareholders’ equity, no minority interest, stood at SAR 1.46 billion as of March 31, 2024, compared to SAR 1.26 billion a year earlier.
Attached Documents
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}